| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Correspondence: Addresss correspondence and reprint requests to: Omgo E. Nieweg, MD, PhD, Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Fax: 31-20-512.2554; E-mail: nieweg{at}nki.nl
Key Words: Sentinel lymph node Definition
| INTRODUCTION |
|---|
|
|
|---|
The urologist Ramon Cabañas1 was one of the first persons to use the name "sentinel lymph node." In 1977, he suggested that squamous cell carcinoma of the penis initially drains to a particular lymph node in the groin that is defined by its constant anatomic position. For penile cancer this assumption appears plausible, because penile cancer is always located in the exact same part of the body, quite unlike the situation in breast cancer and in melanoma.
In the late 1980s, Donald L. Morton, surgeon at the John Wayne Cancer Center in Santa Monica, and his pathologist Alistair J. Cochran (from UCLA) proposed the innovative concept of "lymphatic mapping with sentinel lymph node biopsy" for melanoma.2 They suggested that the node to receive direct drainage from a melanoma could be any one node in a particular lymph node field, depending on the location of the primary lesion and with certain individual variability. By suggesting that other lymph nodes would become involved in a later phase, they revived William S. Halsteds (18521922) concept of sequential lymphatic dissemination.3
Lately, Mortons original definition of a sentinel node is becoming the source of confusion.46 Morton stated: a sentinel node is the initial lymph node upon which the primary tumor drains.2 In other words, the sentinel node (first-tier node, first-echelon node) is the lymph node on the direct drainage pathway from the primary tumor (Fig. 1). Some investigators have changed the definition and have come up with their own definitions.710 This is understandable because specialists from different fields are involved and everybody is looking at this development from his or her own background and perspective. The purpose of this paper is to discuss these various definitions and to suggest a practical way to apply this information in the clinical situation.
|
|
|
Another relevant point is that the brightness of a node on the images not only depends on the amount of radionuclide in that node but also on its distance to the gamma camera. When two nodes containing an equal amount of a radionuclide are situated at a different depth, the node closest to the gamma camera will be depicted as the hottest (Fig. 4). Scatter and absorption explain this phenomenon: the brightness decreases with increasing distance. When two nodes not only have different depths but also different latitudes, one may be the hottest in the anterior view and the other one in the lateral view. So, there are a number of reasons not to use its brightness on the scintigram to decide whether or not a lymph node is a sentinel node.
|
A more refined approach is to define a sentinel node as a node that contains a certain number of times as much radioactivity as the background: the sentinel node-to-background ratio The amount of radioactivity that is accumulated in a lymph node depends on a number of factors, some of which are associated with the type of colloid particles that are used, such as their size, their surface characteristics, and stability. The size of the lymph node, macrophage avidity for the tracer, and the lymph flow rate clearly play a role as well. Lymph flow depends on factors such as physical exercise, medication, massaging of the injection site, and hydration of the patient. Because so many parameters are involved, it is not surprising that tracer uptake in a sentinel node is highly variable. In a study of 60 melanoma patients, uptake in the sentinel node ranged from 0.0013% to 6.8% of the injected tracer dosage.13 In breast cancer, the 95% uptake range was shown to be 0.001% to 2.5% of the injected dose.14
The background count rate is also not the solid denominator it appears to be. Where is the probe placed to determine the background? Most surgeons obtain a background reading within the lymphatic field. This is notoriously variable and depends on the distance to the radioactive node, the distance to the injection site, and the angle at which the device is held. A background reading with a shield applied to the probe is considerably higher than a reading obtained with a collimator applied. A reading without shield or collimator is even higher.
Defining the sentinel node based on the sentinel node-to-nonsentinel node ratio also has its drawbacks. This approach implies that one has to find a nonsentinel node first and than check the other nodes with the probe to determine whether they exceed the designated count rate. Additional exploration is performed and this approach also requires a definition of the characteristics of a nonsentinel node. How many counts are acceptable for a node to be considered a nonsentinel node?
When we add to these considerations the notion that 15% to 30% of the lymph nodes on a direct drainage pathway from a primary breast cancer are not radioactive at all,15,16 one cannot but conclude that the definition of a sentinel node had better not be based solely on factors measurable with the gamma ray detection probe.
Definitions Based on Use of the Vital Dye
Some surgeons remove every lymph node that is stained blue based on the definition of a sentinel node being a blue node. Again, this point of view does not acknowledge the fact that some of the tracer may pass through the first-tier lymph node and stain secondary nodes.
Occasionally, one is faced with a blue-stained lymphatic duct leading up to a lymph node that is not blue itself. Usually a few minutes of patience will be enough for the node to become at least partly stained. However, that may not happen. The ingress of lymph may be obstructed or the lymph flow may have stopped because the duct has suffered damage upstream. It seems reasonable to consider such an unstained node a sentinel node. Occasionally, a lymphatic vessel runs through the lymph node or over its surface without discharging its contents into that node.17
Concluding Remarks
The sentinel node is not a "blue node" or a "node with a certain amount of radioactivity." These characteristics are simply reflections of the technology that is applied to gain insight into the physiology of lymphatic drainage.5 Mortons original definition that a sentinel node is "the first lymph node that receives afferent lymphatic drainage from a primary tumor" best reflects the concept of the stepwise spread of cancer through the lymphatic system. However, this definition is based on the concept and it is not always of help when the nuclear medicine physician and the surgeon find themselves confronted with a clinical situation that is not as clearcut as the theory would suggest. Although excellent results have been described using blue dye or a probe alone, the most practical approach is probably to use all the available detection techniques in the repertoire. The scintigraphy images indicate the area to explore. The gamma ray detection probe can pinpoint the location of radioactive nodes. Careful dissection of the blue lymphatic channels lays out the drainage pattern and identifies the node(s) that receive drainage directly from the primary lesion. When the blue dye approach fails, it is best to err on the safe side and to remove the radioactive nodes that potentially could receive direct drainage from the primary lesion site.
Received for publication July 11, 2000. Accepted for publication February 9, 2001.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
I. M. C. van der Ploeg, R. A. V. Olmos, B. B. R. Kroon, and O. E. Nieweg Tumor-Positive Sentinel Node Biopsy of the Groin in Clinically Node-Negative Melanoma Patients: Superficial or Superficial and Deep Lymph Node Dissection? Ann. Surg. Oncol., May 1, 2008; 15(5): 1485 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. van Rijk, H. J. Teertstra, J. L. Peterse, O. E. Nieweg, R. A. V. Olmos, C. A. Hoefnagel, and B. B. R. Kroon Ultrasonography and Fine-needle Aspiration Cytology in the Preoperative Evaluation of Melanoma Patients Eligible for Sentinel Node Biopsy Ann. Surg. Oncol., November 1, 2006; 13(11): 1511 - 1516. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Shayan, M. G. Achen, and S. A. Stacker Lymphatic vessels in cancer metastasis: bridging the gaps Carcinogenesis, September 1, 2006; 27(9): 1729 - 1738. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Motomura, C. Egawa, Y. Komoike, S. Nagumo, H. Koyama, and H. Inaji Three-Axillary Lymph Node Sampling for the Prediction of Nonsentinel Node Metastases in Breast Cancer Patients With Sentinel Node Metastases Ann. Surg. Oncol., July 1, 2006; 13(7): 985 - 989. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Abdul-Rasool, S H Kidson, E Panieri, D Dent, K Pillay, and G S Hanekom An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J. Clin. Pathol., March 1, 2006; 59(3): 289 - 297. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Estourgie, O. E. Nieweg, R. A. Valdes Olmos, C. A. Hoefnagel, and B. B. R. Kroon Review and Evaluation of Sentinel Node Procedures in 250 Melanoma Patients With a Median Follow-Up of 6 Years Ann. Surg. Oncol., July 1, 2003; 10(6): 681 - 688. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. E. Schmidt, E. A. Woltering, W. R. Webb, O. M. Garcia, J. E. Cohen, and M. H. Rozans Sentinel nodal assessment in patients with carcinoma of the lung Ann. Thorac. Surg., September 1, 2002; 74(3): 870 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Mariani, M. Gipponi, L. Moresco, G. Villa, M. Bartolomei, G. Mazzarol, M. C. Bagnara, A. Romanini, F. Cafiero, G. Paganelli, et al. Radioguided Sentinel Lymph Node Biopsy in Malignant Cutaneous Melanoma* J. Nucl. Med., June 1, 2002; 43(6): 811 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Liptay, S. C. Grondin, W. A. Fry, C. Pozdol, D. Carson, C. Knop, G. A. Masters, R. M. Perlman, and W. Watkin Intraoperative Sentinel Lymph Node Mapping in Non-Small-Cell Lung Cancer Improves Detection of Micrometastases J. Clin. Oncol., April 15, 2002; 20(8): 1984 - 1988. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |